A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Tamsulosin

Tamsulosin hydrochloride capsules are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) [see Clinical Studies (14)].

First FDA approval2010-04-27
Generic availableYes · 12 mfrs
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$465.2M in CY2024 Part D spend32.8M claims · 10.4M beneficiaries · 329 plans surveyed

Lowest NADAC
$0.051/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.051
Across all dosage forms in distribution.
Highest NADAC
$0.051
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Tamsulosin used for?

Tamsulosin hydrochloride capsules are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) [see Clinical Studies (14)].

Is there a generic for Tamsulosin?

Yes. 12 ANDAs filed at FDA, 12 generic manufacturers currently shipping.

How much does my plan pay for Tamsulosin?

Across 329 Part D plans, Tamsulosin averages $0.051/unit (NADAC). Lowest available: $0.051/unit. Highest in distribution: $0.051/unit.

Is Tamsulosin on the FDA shortage list?

Tamsulosin has been discontinued by its manufacturer(s).

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.